Supernus, Inc. - Common Stock (SUPN) stock analysis

SUPN · Supernus, Inc. - Common Stock

Latest recorded price: USD 28.83

Model-estimated fair value: USD 35.44. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic

At $28.83, SUPN trades 18.6% below the model's base-case value of $35.44. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $27.74 in the conservative case and $44.96 in the optimistic case, with a valuation confidence score of 55/100. About 75% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 7.4%, free cash flow margin 6.4%, ROIC -5.6%. The model flags 1 risk signal for this company.

Similar companies in Healthcare